Overview

Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder

Status:
Completed

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Vortioxetine in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder (MDD).

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Treatments:

Duloxetine Hydrochloride
Vortioxetine